Loading
Latest filing published 05 Jan 2024 for Kronos Bio, Inc., €7,978. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Christopher Dinsmore, listed as senior executive, appears in our data through filings on Kronos Bio, Inc. shares, published by SEC (Form 4). Between 2 August 2021 and 4 January 2024, the trades on record add up to 12 filings.
Sales make up the whole of the open-market record (6 sales, €179k). Outside the open market, there are 3 share grants and 3 option exercises. Since January 2024: no purchases and 1 sale on the market.
The record was last updated on 5 January 2024 with an open-market sale (€7,978) in Kronos Bio, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations